首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis.
【24h】

Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis.

机译:184例单纯疱疹病毒性脑炎患者中与阿昔洛韦给药延迟有关的因素。

获取原文
获取原文并翻译 | 示例
           

摘要

The main predictor of outcomes in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation of acyclovir. In this study, factors associated with late initiation of acyclovir were identified. The study included adults from northern France whose cerebrospinal fluid (CSF) was positive for HSV by PCR. Late initiation of acyclovir was defined as a delay of >1 day from hospital admission. In total, 184 patients were retrospectively enrolled from January 1991 to December 2002. The median age was 60 years (range: 17-91), and 102 (55.4%) were male. Acyclovir was initiated >1 day after hospital admission in 68 patients (37.0%). According to multivariate analysis, independent risk factors for late initiation of acyclovir were severe underlying disease (Knaus score >or=C) (OR 4.1; 95% CI 1.5-11.7); alcohol abuse (OR 3.4; 95% CI 1.3-8.9); and a delay of >1 day from admission to first brain imaging (OR 8.4; 95% CI 3.9-18.0). In addition, univariate analysis suggested an association between a finding of <10 leukocytes/mm(3) in CSF at admission (OR 2.5; 95% CI 0.7-5.8). These characteristics were found in 26 (14.1%), 23 (12.5%), 66 (35.9%) and 27 (14.7%) patients, respectively. One risk factor was identified in 109 (59.2%) patients, two in 29 (15.8%), and three in six (3.3%). Patients with HSE often present with severe underlying disease, chronic alcohol abuse, or atypical CSF findings, and such factors should not be allowed to delay diagnosis and administration of acyclovir.
机译:单纯疱疹病毒(HSV)脑炎(HSE)结局的主要预测指标是入院与开始使用阿昔洛韦之间的延迟。在这项研究中,确定了与阿昔洛韦延迟启动相关的因素。该研究包括来自法国北部的成年人,他们的脑脊液(CSF)通过PCR检测为HSV阳性。阿昔洛韦的较晚开始被定义为入院延迟> 1天。从1991年1月至2002年12月,共纳入184例患者。中位年龄为60岁(范围:17-91岁),其中男性102例(55.4%)。 68例患者(37.0%)在入院后1天以上开始使用阿昔洛韦。根据多变量分析,阿昔洛韦迟发的独立危险因素是严重的基础疾病(Knaus评分> or = C)(OR 4.1; 95%CI 1.5-11.7);酗酒(OR 3.4; 95%CI 1.3-8.9);从入院到首次脑部成像的延迟> 1天(OR 8.4; 95%CI 3.9-18.0)。此外,单因素分析表明入院时脑脊液中发现<10白细胞/ mm(3)之间存在关联(OR 2.5; 95%CI 0.7-5.8)。这些特征分别在26(14.1%),23(12.5%),66(35.9%)和27(14.7%)的患者中发现。在109名(59.2%)患者中确定了一种危险因素,在29名(25.8%)中有2名,在6名(3.3%)中有3名。 HSE患者经常表现出严重的基础疾病,慢性酒精滥用或非典型CSF表现,因此不应允许这些因素延迟阿昔洛韦的诊断和给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号